Drug/Small Molecule:
metocurine

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • (+)-O,O'-Dimethylchondrocurarine Di-iodide
  • Dimethyl Tubocurarine Iodide
  • Dimethyltubocurarine Iodide
  • Dimetiltubocurarinio, ioduro de
  • Metocurini Iodidum
  • Metokuriinijodidi
  • Metokurinjodid
  • Trimethyltubocurarine Iodide
  • metocurine iodide
Trade Names
  • Metubine
  • Metubine iodide
  • Mutubine Iodide
Brand Mixture Names

PharmGKB Accession Id:
PA164749507

Description

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation.

Source: Drug Bank

Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.(PMID: 9915319)

Source: Drug Bank

Indication

For use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.

Source: Drug Bank

Metocurine is a muscle relaxant.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Metocurine iodide antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Source: Drug Bank

Metocurine antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Source: Drug Bank

Pharmacology

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of metocurine iodide. Repeated administration of maintenance doses of metocurine iodide has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Protein Binding

35% in plasma

Source: Drug Bank

Half-Life

3 to 4 hours

Source: Drug Bank

Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Source: Drug Bank

Chemical Properties

Chemical Formula

C40H48I2N2O6

Source: Drug Bank

C40H48N2O6

Source: Drug Bank

Isomeric SMILES

C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C

Source: Drug Bank

[H][C@]12CC3=CC=C(OC4=C(OC)C(OC)=CC5=C4[C@@]([H])(CC4=CC(OC6=CC1=C(CC[N+]2(C)C)C=C6OC)=C(OC)C=C4)[N+](C)(C)CC5)C=C3

Source: Drug Bank

C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[I-].[I-]

Source: Drug Bank

[I-].[I-].[H][C@]12CC3=CC=C(OC4=C(OC)C(OC)=CC5=C4[C@@]([H])(CC4=CC(OC6=CC1=C(CC[N+]2(C)C)C=C6OC)=C(OC)C=C4)[N+](C)(C)CC5)C=C3

Source: Drug Bank

Canonical SMILES

[I-].[I-]

Source: Drug Bank

COC1=C2OC3=C(OC)C=C4CC[N+](C)(C)[C@@H]

Source: Drug Bank

Average Molecular Weight

906.6279

Source: Drug Bank

652.8189

Source: Drug Bank

Monoisotopic Molecular Weight

906.160174118

Source: Drug Bank

652.351237278

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
CHRM2 (source: Drug Bank)
CHRNA2 (source: Drug Bank)

Drug Interactions

Drug Description
metocurine The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine Theophylline decreases the effect of muscle relaxant (source: Drug Bank)
metocurine The agent decreases the effect of the muscle relaxant (source: Drug Bank)
metocurine Decreases the effect of muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine Phenytoin decreases the effect of muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine The agent dereases the effect of the muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine Theophylline decreases the effect of muscle relaxant (source: Drug Bank)
metocurine Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank)
metocurine Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of the muscle relaxant (source: Drug Bank)
metocurine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank)
metocurine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank)
metocurine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank)
metocurine The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank)
metocurine Theophylline decreases the effect of the muscle relaxant (source: Drug Bank)
metocurine Theophylline decreases the effect of the muscle relaxant (source: Drug Bank)
metocurine The agent increases the effect of the muscle relaxant (source: Drug Bank)
No related diseases are available

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00416
DB01336
KEGG Compound:
C07919
KEGG Drug:
D00761
PubChem Compound:
21233
24244
PubChem Substance:
10121
166758
46507773
46508044
Drugs Product Database (DPD):
466948
BindingDB:
50094708
ChemSpider:
19961
22666
Therapeutic Targets Database:
DAP000352
DAP000824

Clinical Trials

These are trials that mention metocurine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.